By Cecilia Butini 

Sanofi SA said Tuesday that it won't further advance the development of a messenger-RNA vaccine against Covid-19 and would instead focus on another type of shot, despite reporting positive interim results in a phase 1/2 mRNA trial.

The French pharma major said it wouldn't make sense for it to advance its mRNA vaccine into a phase 3 trial. "From a public-health perspective, mRNA Covid vaccines are widely available today and starting a placebo-controlled study in countries where vaccines are available would be extremely challenging, so it does not make sense for us to further advance our mRNA Covid vaccine into Phase 3," a company spokesman said.

The company had said earlier Tuesday that a phase 1/2 trial for a mRNA vaccine against the coronavirus showed neutralizing antibodies in 91% to 100% of study participants two weeks after a second injection.

Sanofi's work on Covid-19 will now be focused on a vaccine which uses an adjuvanted recombinant protein technology and which it is developing in partnership with GlaxoSmithKline PLC, it said.


Write to Cecilia Butini at


(END) Dow Jones Newswires

September 28, 2021 04:57 ET (08:57 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Sanofi Charts.